 Sarah Parker
Concepts (341)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimicrobial Stewardship | 11 | 2021 | 123 | 4.630 |
Why?
| | Hospitals, Pediatric | 22 | 2022 | 557 | 3.540 |
Why?
| | Anti-Infective Agents | 12 | 2021 | 243 | 3.440 |
Why?
| | Anti-Bacterial Agents | 34 | 2024 | 1906 | 3.010 |
Why?
| | Bacteremia | 4 | 2025 | 219 | 2.140 |
Why?
| | Osteomyelitis | 9 | 2024 | 143 | 2.080 |
Why?
| | Arthritis, Infectious | 7 | 2022 | 73 | 1.920 |
Why?
| | Drug Utilization Review | 6 | 2020 | 61 | 1.590 |
Why?
| | Bacterial Infections | 7 | 2025 | 246 | 1.420 |
Why?
| | Blood Culture | 4 | 2025 | 24 | 1.410 |
Why?
| | Metronidazole | 3 | 2019 | 19 | 1.210 |
Why?
| | Appendicitis | 3 | 2019 | 146 | 1.090 |
Why?
| | Otitis Media | 4 | 2024 | 176 | 1.020 |
Why?
| | Child | 49 | 2025 | 22725 | 1.010 |
Why?
| | Staphylococcal Infections | 5 | 2025 | 397 | 1.010 |
Why?
| | Acute Disease | 8 | 2025 | 1015 | 0.940 |
Why?
| | Kingella kingae | 2 | 2022 | 12 | 0.870 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2025 | 272 | 0.860 |
Why?
| | Retrospective Studies | 27 | 2025 | 16740 | 0.720 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2025 | 242 | 0.710 |
Why?
| | Musculoskeletal System | 1 | 2022 | 49 | 0.700 |
Why?
| | Musculoskeletal Diseases | 2 | 2025 | 87 | 0.690 |
Why?
| | Respiration, Artificial | 2 | 2022 | 705 | 0.650 |
Why?
| | Surgical Wound Infection | 2 | 2022 | 328 | 0.650 |
Why?
| | Humans | 74 | 2025 | 143560 | 0.580 |
Why?
| | Infant | 21 | 2025 | 9981 | 0.560 |
Why?
| | Respiratory Tract Infections | 1 | 2022 | 389 | 0.550 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 198 | 0.540 |
Why?
| | Drug Resistance, Bacterial | 3 | 2021 | 195 | 0.540 |
Why?
| | Medical Order Entry Systems | 1 | 2018 | 44 | 0.530 |
Why?
| | Cefoxitin | 1 | 2017 | 8 | 0.520 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2017 | 49 | 0.520 |
Why?
| | Cephalosporins | 2 | 2015 | 46 | 0.520 |
Why?
| | Ceftriaxone | 1 | 2017 | 21 | 0.520 |
Why?
| | Microbial Sensitivity Tests | 5 | 2024 | 376 | 0.510 |
Why?
| | beta-Lactams | 1 | 2017 | 36 | 0.510 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2017 | 69 | 0.500 |
Why?
| | Interprofessional Relations | 1 | 2019 | 283 | 0.500 |
Why?
| | Child, Preschool | 18 | 2025 | 11737 | 0.490 |
Why?
| | Prescriptions | 1 | 2016 | 74 | 0.490 |
Why?
| | Drug Costs | 1 | 2017 | 115 | 0.490 |
Why?
| | Pneumonia, Bacterial | 1 | 2017 | 116 | 0.490 |
Why?
| | Pyomyositis | 3 | 2022 | 15 | 0.490 |
Why?
| | Communicable Diseases | 4 | 2021 | 165 | 0.470 |
Why?
| | Exanthema | 1 | 2016 | 82 | 0.470 |
Why?
| | Neutropenia | 1 | 2016 | 152 | 0.460 |
Why?
| | Diarrhea | 1 | 2016 | 183 | 0.450 |
Why?
| | Thimerosal | 2 | 2005 | 6 | 0.450 |
Why?
| | Mycobacterium tuberculosis | 4 | 2021 | 332 | 0.440 |
Why?
| | Health Resources | 1 | 2016 | 129 | 0.440 |
Why?
| | Preservatives, Pharmaceutical | 2 | 2005 | 26 | 0.430 |
Why?
| | Inpatients | 4 | 2021 | 521 | 0.430 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 87 | 0.430 |
Why?
| | Decision Support Systems, Clinical | 1 | 2018 | 270 | 0.410 |
Why?
| | Disease Outbreaks | 2 | 2021 | 430 | 0.410 |
Why?
| | Enterovirus Infections | 1 | 2016 | 174 | 0.400 |
Why?
| | Cephalexin | 2 | 2024 | 14 | 0.390 |
Why?
| | Electronic Health Records | 2 | 2019 | 1163 | 0.390 |
Why?
| | Inappropriate Prescribing | 1 | 2013 | 63 | 0.390 |
Why?
| | Guideline Adherence | 1 | 2017 | 574 | 0.380 |
Why?
| | Pandemics | 2 | 2022 | 1668 | 0.380 |
Why?
| | Cross Infection | 3 | 2025 | 261 | 0.370 |
Why?
| | Intensive Care Units, Pediatric | 3 | 2025 | 279 | 0.350 |
Why?
| | Health Personnel | 1 | 2018 | 736 | 0.340 |
Why?
| | Referral and Consultation | 1 | 2017 | 828 | 0.340 |
Why?
| | Vancomycin | 2 | 2023 | 94 | 0.330 |
Why?
| | Liver Abscess, Amebic | 2 | 2009 | 3 | 0.320 |
Why?
| | Phospholipases A | 2 | 2007 | 101 | 0.310 |
Why?
| | Urinary Tract Infections | 2 | 2025 | 200 | 0.310 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1557 | 0.300 |
Why?
| | Stomach Rupture | 1 | 2009 | 3 | 0.300 |
Why?
| | Phospholipases | 1 | 2009 | 14 | 0.300 |
Why?
| | Thiolester Hydrolases | 1 | 2009 | 14 | 0.300 |
Why?
| | Pericardial Effusion | 1 | 2009 | 21 | 0.290 |
Why?
| | Male | 27 | 2025 | 71501 | 0.290 |
Why?
| | Lactones | 1 | 2009 | 58 | 0.280 |
Why?
| | Staphylococcus aureus | 5 | 2024 | 446 | 0.280 |
Why?
| | Peritonitis | 1 | 2009 | 83 | 0.280 |
Why?
| | Pleural Effusion | 1 | 2009 | 60 | 0.280 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2005 | 27 | 0.280 |
Why?
| | Drug Utilization | 3 | 2017 | 166 | 0.280 |
Why?
| | Colorado | 4 | 2020 | 4658 | 0.270 |
Why?
| | Cefadroxil | 2 | 2024 | 8 | 0.260 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2007 | 22 | 0.260 |
Why?
| | Gene Expression Regulation, Bacterial | 2 | 2009 | 327 | 0.260 |
Why?
| | Cost Savings | 2 | 2017 | 86 | 0.260 |
Why?
| | Female | 24 | 2025 | 77252 | 0.250 |
Why?
| | Time Factors | 4 | 2024 | 7032 | 0.250 |
Why?
| | Dermatomycoses | 1 | 2006 | 8 | 0.250 |
Why?
| | Pharmacy Service, Hospital | 2 | 2017 | 85 | 0.240 |
Why?
| | Infant, Newborn | 7 | 2025 | 6366 | 0.240 |
Why?
| | Adolescent | 15 | 2025 | 22482 | 0.240 |
Why?
| | Drug Approval | 1 | 2006 | 89 | 0.240 |
Why?
| | Mycobacterium | 1 | 2007 | 112 | 0.230 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2006 | 129 | 0.230 |
Why?
| | Infection Control | 3 | 2015 | 173 | 0.230 |
Why?
| | Intellectual Property | 1 | 2005 | 7 | 0.230 |
Why?
| | Autistic Disorder | 2 | 2005 | 212 | 0.220 |
Why?
| | Measles | 1 | 2025 | 48 | 0.220 |
Why?
| | Mycoses | 1 | 2025 | 87 | 0.220 |
Why?
| | Simplexvirus | 1 | 2004 | 82 | 0.210 |
Why?
| | Encephalitis, Viral | 1 | 2004 | 45 | 0.210 |
Why?
| | Bacterial Proteins | 2 | 2018 | 944 | 0.210 |
Why?
| | Limbus Corneae | 1 | 2023 | 9 | 0.210 |
Why?
| | Herpes Simplex | 1 | 2004 | 94 | 0.210 |
Why?
| | Amoxicillin | 1 | 2024 | 35 | 0.200 |
Why?
| | Lymphadenitis | 1 | 2023 | 6 | 0.200 |
Why?
| | Hospitalization | 5 | 2023 | 2313 | 0.200 |
Why?
| | Drug Administration Schedule | 3 | 2017 | 773 | 0.190 |
Why?
| | Drainage | 2 | 2017 | 182 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 162 | 0.190 |
Why?
| | Cisplatin | 1 | 2024 | 333 | 0.190 |
Why?
| | Exosomes | 1 | 2023 | 108 | 0.190 |
Why?
| | Databases, Factual | 4 | 2025 | 1465 | 0.190 |
Why?
| | Exudates and Transudates | 1 | 2021 | 12 | 0.180 |
Why?
| | Machine Learning | 2 | 2025 | 574 | 0.180 |
Why?
| | Cross-Over Studies | 1 | 2024 | 583 | 0.180 |
Why?
| | Immunotherapy | 1 | 2006 | 659 | 0.170 |
Why?
| | Fluoroquinolones | 1 | 2021 | 43 | 0.170 |
Why?
| | Risk Adjustment | 1 | 2021 | 84 | 0.170 |
Why?
| | Fever | 2 | 2017 | 310 | 0.170 |
Why?
| | Antibiotic Prophylaxis | 1 | 2022 | 128 | 0.170 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 91 | 0.160 |
Why?
| | Hospitals | 3 | 2021 | 691 | 0.160 |
Why?
| | Delayed Diagnosis | 1 | 2021 | 91 | 0.160 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.160 |
Why?
| | Treatment Outcome | 7 | 2024 | 11365 | 0.160 |
Why?
| | Meningitis | 1 | 2021 | 81 | 0.160 |
Why?
| | Laboratories | 1 | 2021 | 107 | 0.160 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2020 | 104 | 0.160 |
Why?
| | Trachea | 1 | 2021 | 250 | 0.160 |
Why?
| | Bacteroides fragilis | 1 | 2019 | 14 | 0.160 |
Why?
| | Encephalitis | 1 | 2021 | 137 | 0.150 |
Why?
| | Appendectomy | 2 | 2017 | 89 | 0.150 |
Why?
| | Monte Carlo Method | 1 | 2019 | 154 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 875 | 0.150 |
Why?
| | Neisseriaceae Infections | 1 | 2018 | 6 | 0.150 |
Why?
| | Pediatrics | 3 | 2017 | 1124 | 0.150 |
Why?
| | Autophagy | 1 | 2021 | 287 | 0.150 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1474 | 0.150 |
Why?
| | Area Under Curve | 1 | 2019 | 327 | 0.150 |
Why?
| | Entamoeba histolytica | 2 | 2009 | 10 | 0.150 |
Why?
| | Hospital Records | 1 | 2018 | 10 | 0.140 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 642 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1161 | 0.140 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 1058 | 0.140 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 272 | 0.140 |
Why?
| | Medical Records Systems, Computerized | 1 | 2018 | 96 | 0.140 |
Why?
| | Hydrolysis | 2 | 2009 | 198 | 0.130 |
Why?
| | Tuberculosis | 1 | 2021 | 290 | 0.130 |
Why?
| | Patient Readmission | 3 | 2017 | 706 | 0.130 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2009 | 397 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1252 | 0.130 |
Why?
| | Abdominal Abscess | 1 | 2017 | 25 | 0.130 |
Why?
| | Central Venous Catheters | 1 | 2017 | 50 | 0.130 |
Why?
| | MicroRNAs | 1 | 2023 | 698 | 0.130 |
Why?
| | Abscess | 1 | 2017 | 77 | 0.130 |
Why?
| | Administration, Oral | 2 | 2016 | 842 | 0.130 |
Why?
| | Medical Records | 1 | 2017 | 185 | 0.130 |
Why?
| | Communicable Disease Control | 1 | 2017 | 86 | 0.120 |
Why?
| | Drug Substitution | 1 | 2017 | 63 | 0.120 |
Why?
| | Drug Resistance | 1 | 2017 | 153 | 0.120 |
Why?
| | Amino Acid Sequence | 4 | 2009 | 2165 | 0.120 |
Why?
| | Pharmacists | 1 | 2019 | 260 | 0.120 |
Why?
| | Rural Population | 1 | 2021 | 617 | 0.120 |
Why?
| | Drug Prescriptions | 1 | 2018 | 275 | 0.120 |
Why?
| | Osteoarthritis | 1 | 2018 | 211 | 0.120 |
Why?
| | Molecular Sequence Data | 4 | 2009 | 2942 | 0.120 |
Why?
| | Aftercare | 1 | 2017 | 218 | 0.120 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 1984 | 0.120 |
Why?
| | Administration, Intravenous | 1 | 2016 | 173 | 0.120 |
Why?
| | Cell Wall | 2 | 2021 | 61 | 0.120 |
Why?
| | Length of Stay | 2 | 2020 | 1279 | 0.120 |
Why?
| | United States | 9 | 2025 | 15554 | 0.110 |
Why?
| | Knowledge Management | 1 | 2014 | 2 | 0.110 |
Why?
| | Community-Acquired Infections | 1 | 2017 | 179 | 0.110 |
Why?
| | Radiography | 1 | 2017 | 846 | 0.110 |
Why?
| | Clostridium Infections | 1 | 2015 | 74 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1089 | 0.110 |
Why?
| | Prospective Studies | 3 | 2024 | 7900 | 0.100 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 621 | 0.100 |
Why?
| | Postoperative Care | 1 | 2016 | 281 | 0.100 |
Why?
| | Medication Therapy Management | 1 | 2014 | 79 | 0.100 |
Why?
| | Antitubercular Agents | 2 | 2021 | 213 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 831 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2195 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 3 | 2009 | 2779 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2017 | 601 | 0.090 |
Why?
| | Drug Monitoring | 1 | 2016 | 396 | 0.090 |
Why?
| | Quality of Health Care | 1 | 2017 | 650 | 0.090 |
Why?
| | Risk Assessment | 2 | 2016 | 3577 | 0.090 |
Why?
| | Laparoscopy | 1 | 2017 | 474 | 0.090 |
Why?
| | Genotype | 3 | 2021 | 1877 | 0.090 |
Why?
| | Drug Hypersensitivity | 1 | 2013 | 95 | 0.090 |
Why?
| | Bacteria | 3 | 2023 | 888 | 0.090 |
Why?
| | Physicians | 1 | 2019 | 940 | 0.080 |
Why?
| | Cohort Studies | 2 | 2017 | 5891 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2014 | 783 | 0.080 |
Why?
| | Paromomycin | 1 | 2009 | 3 | 0.080 |
Why?
| | Mycolic Acids | 1 | 2009 | 7 | 0.070 |
Why?
| | Trophozoites | 1 | 2009 | 4 | 0.070 |
Why?
| | Young Adult | 4 | 2021 | 13972 | 0.070 |
Why?
| | Antiprotozoal Agents | 1 | 2009 | 15 | 0.070 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1207 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1362 | 0.070 |
Why?
| | DNA, Protozoan | 1 | 2008 | 32 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2056 | 0.070 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2009 | 130 | 0.070 |
Why?
| | Nitrobenzenes | 1 | 2007 | 17 | 0.070 |
Why?
| | Chromatography, Thin Layer | 1 | 2007 | 25 | 0.070 |
Why?
| | Polysorbates | 1 | 2007 | 41 | 0.060 |
Why?
| | Terminology as Topic | 1 | 2009 | 250 | 0.060 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3611 | 0.060 |
Why?
| | Injections, Intravenous | 2 | 2017 | 203 | 0.060 |
Why?
| | Membrane Lipids | 1 | 2007 | 82 | 0.060 |
Why?
| | Animals | 6 | 2024 | 38010 | 0.060 |
Why?
| | Selection, Genetic | 1 | 2008 | 266 | 0.060 |
Why?
| | Maximum Tolerated Dose | 1 | 2006 | 205 | 0.060 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1369 | 0.060 |
Why?
| | Measles Vaccine | 1 | 2025 | 21 | 0.060 |
Why?
| | United States Food and Drug Administration | 1 | 2006 | 202 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 839 | 0.060 |
Why?
| | Aminopeptidases | 1 | 2024 | 22 | 0.060 |
Why?
| | Ethylmercury Compounds | 1 | 2004 | 1 | 0.060 |
Why?
| | Risk Factors | 2 | 2016 | 10644 | 0.060 |
Why?
| | Diphtheria-Tetanus Vaccine | 1 | 2004 | 5 | 0.060 |
Why?
| | Methylmercury Compounds | 1 | 2004 | 9 | 0.050 |
Why?
| | Drug Industry | 1 | 2005 | 48 | 0.050 |
Why?
| | Aphasia | 1 | 2004 | 23 | 0.050 |
Why?
| | Mass Spectrometry | 2 | 2025 | 740 | 0.050 |
Why?
| | Patient Discharge | 2 | 2025 | 923 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1504 | 0.050 |
Why?
| | Half-Life | 1 | 2004 | 147 | 0.050 |
Why?
| | North America | 1 | 2025 | 308 | 0.050 |
Why?
| | Escherichia coli | 1 | 2009 | 834 | 0.050 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.050 |
Why?
| | Streptococcus pyogenes | 1 | 2004 | 42 | 0.050 |
Why?
| | Acyclovir | 1 | 2004 | 96 | 0.050 |
Why?
| | Adult | 5 | 2021 | 40012 | 0.050 |
Why?
| | Child Development Disorders, Pervasive | 1 | 2004 | 62 | 0.050 |
Why?
| | Hematologic Neoplasms | 1 | 2006 | 162 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2023 | 3380 | 0.050 |
Why?
| | Vomiting | 1 | 2004 | 129 | 0.050 |
Why?
| | beta-Lactamases | 1 | 2024 | 50 | 0.050 |
Why?
| | Kinetics | 1 | 2007 | 1628 | 0.050 |
Why?
| | Sulbactam | 1 | 2023 | 6 | 0.050 |
Why?
| | Ampicillin | 1 | 2023 | 14 | 0.050 |
Why?
| | Nasopharynx | 1 | 2023 | 73 | 0.050 |
Why?
| | Stromal Cells | 1 | 2023 | 128 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2023 | 63 | 0.050 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 53 | 0.050 |
Why?
| | Cephalothin | 1 | 2022 | 5 | 0.050 |
Why?
| | Oxacillin | 1 | 2022 | 5 | 0.050 |
Why?
| | Pneumonia | 1 | 2009 | 647 | 0.050 |
Why?
| | Type C Phospholipases | 1 | 2002 | 71 | 0.050 |
Why?
| | Methicillin | 1 | 2022 | 10 | 0.050 |
Why?
| | Cefazolin | 1 | 2022 | 22 | 0.050 |
Why?
| | Cornea | 1 | 2023 | 161 | 0.050 |
Why?
| | Butanes | 1 | 2021 | 4 | 0.040 |
Why?
| | Cell Extracts | 1 | 2021 | 21 | 0.040 |
Why?
| | DNA Glycosylases | 1 | 2021 | 8 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 354 | 0.040 |
Why?
| | Cell Communication | 1 | 2023 | 313 | 0.040 |
Why?
| | Gestational Age | 1 | 2025 | 970 | 0.040 |
Why?
| | Ubiquinone | 1 | 2021 | 35 | 0.040 |
Why?
| | Pyridinium Compounds | 1 | 2021 | 30 | 0.040 |
Why?
| | Streptococcus pneumoniae | 1 | 2023 | 174 | 0.040 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 47 | 0.040 |
Why?
| | Megakaryocytes | 1 | 2021 | 35 | 0.040 |
Why?
| | Arkansas | 1 | 2021 | 22 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2004 | 292 | 0.040 |
Why?
| | Microbiology | 1 | 2021 | 24 | 0.040 |
Why?
| | Reference Standards | 1 | 2021 | 181 | 0.040 |
Why?
| | Seizures | 1 | 2004 | 454 | 0.040 |
Why?
| | Organophosphorus Compounds | 1 | 2021 | 82 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2021 | 153 | 0.040 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2021 | 165 | 0.040 |
Why?
| | Drug Combinations | 1 | 2021 | 372 | 0.040 |
Why?
| | Myositis | 1 | 2020 | 52 | 0.040 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2021 | 187 | 0.040 |
Why?
| | Pseudomonas aeruginosa | 1 | 2002 | 361 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2021 | 251 | 0.040 |
Why?
| | Neoplasms | 2 | 2025 | 2804 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2020 | 177 | 0.040 |
Why?
| | Feces | 2 | 2015 | 496 | 0.040 |
Why?
| | Clindamycin | 1 | 2018 | 14 | 0.040 |
Why?
| | Developed Countries | 1 | 2018 | 38 | 0.040 |
Why?
| | Hospital Charges | 1 | 2018 | 44 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5743 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1487 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2021 | 589 | 0.030 |
Why?
| | Methyltransferases | 1 | 2018 | 73 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 2018 | 67 | 0.030 |
Why?
| | Research Design | 1 | 2004 | 1123 | 0.030 |
Why?
| | Medical Staff, Hospital | 1 | 2018 | 81 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 15 | 0.030 |
Why?
| | Metformin | 1 | 2021 | 331 | 0.030 |
Why?
| | Age Distribution | 1 | 2018 | 398 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 383 | 0.030 |
Why?
| | Blood Platelets | 1 | 2021 | 390 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2025 | 1058 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2023 | 1125 | 0.030 |
Why?
| | Benchmarking | 1 | 2018 | 183 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1217 | 0.030 |
Why?
| | Mice | 2 | 2021 | 18378 | 0.030 |
Why?
| | Myocardium | 1 | 2021 | 928 | 0.030 |
Why?
| | Vaccination | 1 | 2025 | 1484 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1678 | 0.030 |
Why?
| | Lung | 1 | 2009 | 4101 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2016 | 247 | 0.030 |
Why?
| | Genomics | 1 | 2021 | 831 | 0.030 |
Why?
| | Algorithms | 1 | 2023 | 1813 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1114 | 0.030 |
Why?
| | Alcoholism | 1 | 2021 | 838 | 0.030 |
Why?
| | Inservice Training | 1 | 2014 | 119 | 0.030 |
Why?
| | Asthma | 1 | 2006 | 1918 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2177 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2021 | 2020 | 0.020 |
Why?
| | Kidney | 1 | 2021 | 1507 | 0.020 |
Why?
| | Substrate Specificity | 2 | 2004 | 383 | 0.020 |
Why?
| | Medical Oncology | 1 | 2015 | 328 | 0.020 |
Why?
| | Brain | 1 | 2004 | 2892 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1394 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4522 | 0.020 |
Why?
| | Dysentery, Amebic | 1 | 2008 | 2 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 6025 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3625 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1062 | 0.010 |
Why?
| | Prophages | 1 | 2004 | 8 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2016 | 2887 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 576 | 0.010 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2002 | 144 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 334 | 0.010 |
Why?
| | Choline | 1 | 2002 | 133 | 0.010 |
Why?
| | Alleles | 1 | 2004 | 893 | 0.010 |
Why?
| | Phospholipids | 1 | 2002 | 212 | 0.010 |
Why?
| | Hemolysis | 1 | 2002 | 213 | 0.010 |
Why?
| | Base Sequence | 1 | 2004 | 2199 | 0.010 |
Why?
| | Calcium | 1 | 2002 | 1183 | 0.010 |
Why?
| | Aged | 1 | 2009 | 25322 | 0.000 |
Why?
| | Middle Aged | 1 | 2009 | 35343 | 0.000 |
Why?
|
|
Parker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|